Janus Kinase 1 in Vitiligo & Psoriasis

Study Overview
=================
Brief Summary
-----------------
Assessment of the level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB which is considered a gold standard therapy for both diseases.

Official Title
-----------------
Expression of Janus Kinase 1 in Vitiligo and Psoriasis Before and After Narrow Band UVB: a Case-Control Study

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Other: skin biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age above 12 years of age. psoriasis vulgaris or non-segmental vitiligo patients who received no systemic or topical treatment at least 6 weeks prior to enrollment into the study. Exclusion Criteria: psoriasis patients with erythrodermic psoriasis, pustular psoriasis or associated psoriatic arthritis vitiligo patients with segmental or universal vitiligo were excluded from the study. any patient with a photosensitive disorder or any contraindication to phototherapy exposure, e.g., history or presence of malignant or premalignant skin lesions.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vitiligo<br>assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB | Other: skin biopsy<br>* Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.<br>|
| Active Comparator: psoriasis<br>assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB | Other: skin biopsy<br>* Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.<br>|
| Other: controls<br>assess the level of JAK1 in controls | Other: skin biopsy<br>* Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of the tissue level of JAK1 in both vitiligo and psoriasis patients before and after treatment with NB-UVB |  | 1 year |